Biopharmaceutical company Astria Therapeutics Inc (NASDAQ: ATXS) announced on Monday that it has been granted Orphan Drug Designation by the U.S. FDA for navenibart (STAR-0215), its monoclonal antibody inhibitor of plasma kallikrein, aimed at treating hereditary angioedema (HAE).
Navenibart is designed to prevent HAE attacks through long-acting administration.
Early results from the Phase 1b/2 ALPHA-STAR trial showed a 90-96% reduction in monthly attack rates with once or twice dosing over six months.
The FDA's Orphan Drug program supports therapies targeting rare diseases, providing development incentives to sponsors.
Navenibart also holds Fast Track Designation, positioning it for rapid regulatory progress.
Hyperion Biosystems and Colorcon sign licensing agreement
Gensco Pharma acquires RizaFilm and RizaPort global rights and IP
Hoth Therapeutics reports positive HT-KIT preclinical results
Tristel secures FDA clearance for Ophthalmic Disinfectant Tristel OPH
Ondine Biomedical joins CAN Health Network to advance Steriwave adoption in Canada
ValiRx subsidiary Inaphaea extends drug repurposing deal with Dominion Biotech
Adcentrx's ADRX-0706 granted US FDA Fast Track designation to treat advanced cervical cancer
AstraZeneca secures EU approval for Calquence combo as first-line treatment in mantle cell lymphoma